Bristol-Myers Squibb Company (BMY) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
Bristol-Myers Squibb (BMY) Q2 2026: Growth Portfolio Now 60% of Sales, Pipeline Readouts Poised to Reshape Long-Term Trajectory
July 30, 2026
15
Bristol-Myers Squibb (BMY) Q4 2025: Growth Portfolio Hits 60% of Revenue as Legacy Step-Down Looms
June 15, 2026
14
Bristol-Myers Squibb (BMY) Q1 2026: Growth Portfolio Climbs 9% as Pipeline Readouts Set Stage for Second-Half Inflection
April 30, 2026
21
Bristol Myers Squibb (BMY) Q3 2025: Growth Portfolio Up 17% as Pipeline Catalysts Accelerate
October 30, 2025
23
Bristol-Myers Squibb (BMY) Q2 2025: Growth Portfolio Jumps 17% as Pipeline and Partnerships Recast Trajectory
July 31, 2025
24
Bristol-Myers Squibb (BMY) Q1 2025: Growth Portfolio Climbs 18% as Pipeline Readouts Set Stage for Decade-End Reacceleration
July 01, 2025
Bristol-Myers Squibb (BMY) Q3 2024: Growth Portfolio Hits 50% of Sales as Neuroscience Launch Reshapes Outlook
October 31, 2024
Bristol Myers Squibb (BMY) Q2 2024: Growth Portfolio Now 46% of Sales, Pipeline Catalysts Build Into 2025
July 26, 2024
Bristol-Myers Squibb (BMY) Q1 2024: Growth Portfolio Hits 40% of Revenue as $1.5B Cost Reset Accelerates Pipeline Focus
April 25, 2024
Bristol-Myers Squibb (BMY) Q4 2023: Growth Portfolio Delivers 15% Expansion, Offsetting Legacy Erosion
February 02, 2024
15
Bristol Myers Squibb (BMY) Q3 2023: New Product Portfolio Guidance Cut to $3.5B, Highlighting Launch Drag and Pipeline Bet
October 26, 2023
25
Bristol-Myers Squibb (BMY) Q2 2023: $1B Revlimid Hit Shifts Guidance, New Portfolio Annualizes at $3.5B
July 27, 2023
Bristol Myers Squibb (BMY) Q1 2023: New Product Sales Double, Diversification Accelerates Pipeline Renewal
April 27, 2023

Browse all companies